The Federal Trade Commission (FTC) welcomes the Biden administration’s efforts to implement a new guidance framework that would permit government agencies to consider the price of an invention when deciding whether to invoke their federal authority to override the privately-held patent of an invention, but is urging the administration to also take action against drug industry patent abuses to further ensure lower prescription drug costs for patients and the government. The commission’s Feb. 6 comments supporting the administration’s draft march-in...